His PSA is high.
What comes next?
Discover a blood test that gives clinicians more clarity on prostate cancer risk.
The IsoPSA Test helps determine if elevated PSA came from cancer cells.
The IsoPSA Test analyzes the structure of the PSA protein, providing more biological certainty around whether an elevated PSA is due to cancer or not.
Reduce over-detection & over-treatment
The IsoPSA Test more than the doubles specificity of Total and % Free PSA;
sensitivity remains at or above 90% across all three measures.1
Predict risk of
clinically significant prostate cancer (csPCa)
over time
A single IsoPSA Test result accurately predicts csPCa over 2.5 years.2
IsoPSA Index ≤ 6
Demonstrated low risk of csPCa, providing confidence to defer biopsy or extend intervals between biopsies.
IsoPSA Index > 6
Nearly 50% develop csPCa within 2.5 years (30 months), indicating closer monitoring and follow-up is warranted.
Simple patient selection with limited exclusion criteria
Only a blood sample is needed; no additional patient information is required
Results are not affected by BPH medications
Includes total PSA result, eliminating need for repeat PSA test
The test provides a simple report to facilitate better patient counseling.
FAQs
The IsoPSA Test is covered by Medicare for eligible male beneficiaries who meet applicable Medicare coverage criteria. Coverage may vary based on insurance carrier and plan type.
If you have questions about insurance coverage, please call (216) 474-0100 or email PatientBilling@clevelanddx.com.
Please contact our Client Services team for assistance at (833) 265 7337 or request information here.
If submitted to Cleveland Diagnostics Laboratory, results will be ready in 3-5 business days after the blood is collected.
More information can be found at isopsa.com/for-patients. Questions can be submitted to our Client Services team here or at (833) 265 7337.
1. Klein, et al. Urol Oncol. 2022 Sep;40(9):408.e9-408.e18.
2. Abdallah, et al. Urology. 2025 Jan 15:S0090-4295(25)00031-7.